cancer immunotherapy 

Statements about this table:
2 antibody be approve for cancer immunotherapy in 2004
most of the antibody that be approve be humanize
the most recent brand to get approve be adcertris
zevalin be the only brand that be type murine
only 1 antibody be approve for cancer immunotherapy each year
none of the antibody have the save target as any other
the most recent brand to get approve be erbitux
only 2 brand have the murine type
antibody
brand name
approval date
type
target
alemtuzumab
campath
2001
humanized
cd52
bevacizumab
avastin
2004
humanized
vascular endothelial growth factor
brentuximab vedotin
adcetris
2011
chimeric
cd30
cetuximab
erbitux
2004
chimeric
epidermal growth factor receptor
gemtuzumab ozogamicin
mylotarg
2000
humanized
cd33
antibody
brand name
approval date
type
target
ibritumomab tiuxetan
zevalin
2002
murine
cd20
panitumumab
vectibix
2006
human
epidermal growth factor receptor
rituximab
rituxan , mabthera
1997
chimeric
cd20
trastuzumab
herceptin
1998
humanized
erbb2